Bringing you the latest news, research and reviews, exclusive interviews, podcasts, quizzes, and more. A peer-reviewed clinical journal serving healthcare professionals working with the Department of Veterans Affairs, the Department of Defense, and the Public Health Service.
Statins have disease-modifying potential in people with noncirrhotic chronic liver disease CLD by reducing the risk for progression to severe liver disease, new research shows.
Their study was published online in Clinical Gastroenterology and Hepatology. Carey, acting head of the hepatology section, department of gastroenterology, hepatology, and nutrition, Cleveland Clinic. Carey added. Sharma and coauthors wrote. A few prior studies have looked at the effects of statins in noncirrhotic CLD specifically, but most only included patients with viral hepatitis , and the identification of precirrhotic liver disease was largely based on fibrosis scores or ICD coding, leading to a risk for misclassification and heterogeneity in results, they wrote.
Using histopathology data in a nationwide Swedish cohort, Dr. Sharma and colleagues identified adults with noncirrhotic CLD who were statin users and a like number of propensity score—matched nonstatin users with noncirrhotic CLD. The adults with CLD included in the study were required to have a liver biopsy showing fibrosis or inflammation between the years and and at least one ICD code for CLD. The analysis found 6. Statin use had a protective association in both prefibrosis and fibrosis stages at diagnosis, the researchers reported.
(mh=Qh3nLqaTZFOC_g6k)4.jpg "Call girl in Neuss")
Statin use was also associated with lower rates of progression to cirrhosis HR, 0. Friedman, MD, chief of the division of liver diseases and dean for therapeutic discovery at the Icahn School of Medicine at Mount Sinai.
